Warning letter
Montana Compounding Pharmacy PC: warning letter of May 9, 2018
FDA warning letter 521947 · Los Angeles District Office
Key facts
| Reference number | 521947 |
|---|---|
| Company | Montana Compounding Pharmacy PC |
| Subject | Compounding Pharmacy/Adulterated Drug Products |
| Issue date | May 9, 2018 |
| Posted date | May 9, 2018 |
| Issuing office | Los Angeles District Office |
| Product type | Drugs |
| CFR sections cited | 216, 200.10(b), 211.42(b), 211.56(a), 211.84(d)(2), 211.84(d)(6), 211.166(a), 210.1(b) |
| Inspection city | Missoula |
| Inspection ZIP | 59802 |
| Inspection start date | Aug 30, 2016 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: